News chronological

Showing 10 items since 1129851

AMERICANTHINKER - The Mohammunist Manifesto—The Promise of ‘Transitional Phase’ Slaughter

American Thinker AI By Milli Sands Both systems promise that a slaughter is necessary but also promise its end. Both systems invariably keep the first promise and violate the second.

Keywordsislamismradical-leftred-green-axisnational-securitypolitical-extremismideologyviolencepolitical-strategyus-policysocial-instabilityreligious-extremismmanifestotransitional-phaseamerican-politics

WASHINGTONPOST (Victoria Craw) - Trump says Secret Service told him to switch planes because of threat

In his first public comments on the operation, the president downplayed the risks to officials and journalists who remained on Air Force One for the flight from Turkey.

Keywordstrumpsecret-serviceair-force-onethreatpresidential-securityus-politicswashington-postflight-safetytravel-logisticsnational-securityintelligenceaviation-securityturkeyforeign-diplomacygeopolitics

YOUTUBE (MS NOW) - MAJOR UPSET: David Crowley WINS Democratic nomination for Wisconsin Governor, BEATS Francesca Hong

Click to play Video
▶️

Milwaukee County Executive David Crowley has secured the Democratic nomination for governor of Wisconsin over Democratic Socialist Francesca Hong. Crowley was ahead of Hong by roughly 3,200 votes when the race was called, and because Hong has now conceded, there will be no recount. MS NOW’s Hunter Woodall joins Way Too Early with a recap of all the primary races.

Who were the primary candidates for the Democratic nomination for Governor of Wisconsin?
The candidates were Milwaukee County Executive David Crowley and Democratic Socialist Francesca Hong.
Q&A ID c1e58fdd-b6f5-4867-8914-a79d5d4ba12c
Will there be a recount in the Democratic primary race for the Wisconsin Governor?
There will be no recount because Francesca Hong has conceded the race.
Q&A ID f9ad1317-5ddc-4962-b9a2-814025e4e44b
What was the margin of victory for David Crowley over Francesca Hong in the Wisconsin Democratic gubernatorial primary?
David Crowley was ahead of Francesca Hong by approximately 3,200 votes at the time the race was called.
Q&A ID 516fd4d7-be0c-4cab-a8b7-8267b1d7c8dd
Who won the Democratic nomination for the Governor of Wisconsin in the primary election?
Milwaukee County Executive David Crowley won the Democratic nomination for governor of Wisconsin, defeating Francesca Hong.
Q&A ID c39ab9dd-d401-4c1c-a677-4115d5e1a15f
Keywordswisconsindavid-crowleyfrancesca-hongdemocratic-primarygovernormilwaukeeelection-upsetpoliticsmidtermsvotingdemocratic-nominationwisconsin-politicsred-green-axismsnbcway-too-early

NEWSCATS (MeighTimbol) - NYPD Rejects City Hall Claim of Police Escort for Mamdani’s Wife on Syria-Lebanon Trip

Rama Duwajo, 29, will jet off to Syria and Lebanon towards the end of next month without taxpayer funded security detail after the NYPD shut down the mayor’s allegation request Reported by: Cherry Meigh TimbolNews [...]

Keywordsnypdzohran-mamdanirama-duwajocity-hallsyrialebanonnew-york-citypoliticsnyc-politicspublic-safetysecurity-detailtravel-advisorytaxpayerspolitical-controversydemocrats

AXIOS (Adriel Bettelheim) - AI brings savings to clinical trials: study

Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. - That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in…

What are the identified limitations or challenges regarding the use of AI in clinical trials?
AI does not guarantee trial success, as challenges such as finding the right patients, obtaining consent, and drug manufacturing/distribution remain. Additionally, the need for humans to verify the work of AI agents could offset some of the time savings.
Q&A ID 958b07ad-3e8d-427d-9277-7282fa3e65f5
What are some potential additional uses for AI agents in clinical trials according to Medable officials?
AI agents could be used to track the diversity of the trial population to ensure treatments work for a broad population, and they can enable researchers to understand the safety and effectiveness of a drug earlier, allowing researchers to focus on more strategic work.
Q&A ID ead0ec93-1535-481a-bf19-78d4889800e8
What timeline do Medable officials provide for AI agents becoming standard features in some clinical trials?
Medable officials suggest that AI agents could become standard features of some clinical trials in three to five years, functioning similarly to self-driving cars to handle record-keeping for new drug approval applications.
Q&A ID 01f72621-e4b0-4f74-b424-605111b905e0
What specific efficiencies were observed when Tufts applied a Medable clinical monitoring agent to a phase 2 and 3 oncology drug development program?
Ken Getz, the executive director of the Tufts center, stated that deploying the agent led to efficiencies such as accelerating enrollment in the trial, reducing the number of on-site visits, and locking in the data.
Q&A ID f19c4457-74f0-44f7-8dc8-fcee459514fb
How does the potential net benefit of an experimental cancer treatment change based on the number of tumors it can target, according to research from Tufts?
Efficiencies increase with the number of tumors a drug can target; for example, an experimental treatment with 50 active uses could see net benefits of as much as $565 million.
Q&A ID f1e36742-7ff3-4ae7-9322-ccb357fae820
According to a Tufts Center for the Study of Drug Development analysis, what are the estimated time and cost benefits of using AI agents in late-stage cancer drug clinical trials?
AI agents can accelerate the clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials.
Q&A ID 67e9a6eb-d3ee-4bb2-8940-8eae4453f298
Keywordsaiartificial-intelligenceclinical-trialshealthcaremedicineoncologycancer-researchdrug-developmentbiotechmedtechcost-savingsefficiencypharmapharmaceutical-industrymedical-innovationdata-analysispatient-enrollmentmedical-technologybiopharmahealth-tech